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Malaria is caused by the parasite Plasmodium falciparum and is amongst the world’s 
most deadly infectious diseases for which there is no vaccine. Malaria is currently controlled 
through drug therapy, but the formation of resistance is common and new drugs that target novel 
parasite functions are urgently needed. P. falciparum contains non-photosynthetic organelle 
known as the apicoplast. The apicoplast harbors its own DNA and a single DNA polymerase 
(apPOL) is targeted to the apicoplast to carry-out genomic replication and repair. apPOL has no 
direct ortholog with mammalian polymerases, making it an appealing drug target for the 
treatment and/or prevention of malaria. The Medicines for Malaria Venture (MMV) selected 400 
structurally diverse compounds that resulted from very large-scale screening campaigns 
performed by St. Jude Children's Research Hospital, Novartis, and GSK. These compounds are 
able to kill P. falciparum in cultured red blood cells and are non-toxic to cultured human cells, 
but their molecular targets are unknown. We previously screened the Malaria Box for apPOL 
inhibitors and identified a single compound (MMV666123) that completely inhibits apPOL at a 
concentration of 10 µM. This thesis describes the kinetic characterization of that compound, 
along with 36 additional structural derivatives that were generated by our collaborators in an 
effort to improve inhibitor potency. In addition, to guide the synthesis of additional derivatives, 
we determined the x-ray crystal structure of one of the derivatives bound to apPOL. The 
compound binds at a previously unidentified allosteric pocket that sits adjacent to the polymerase 
active site. We propose that the binding of the derivative to the allosteric site prevents the 
polymerase from adopting the closed, active conformation of the enzyme. The allosteric site is 
present in other A-family polymerases, but the identity of the residues lining the pocket differ, 





CHAPTER 1. INTRODUCTION 
Literature Review 
Malaria 
For humans, one of the deadliest creatures on earth is the mosquito. Nearly 220 million 
people die every year because of diseases that are transmitted through mosquito bites (1). Out of 
these, 600,000 deaths occur due to malaria alone (2). Parasites from the genus Plasmodium are 
responsible for Malaria with five species infecting humans: Plasmodium 
falciparum; Plasmodium vivax; Plasmodium ovale; Plasmodium malariae; and Plasmodium 
knowlesi. Among these five species, the deadliest is P. falciparum, which especially poses a 
great threat to tropical and the subtropical regions that include Africa, Asia, and Latin America 
(3). 
   P. falciparum follows a complex lifecycle that is divided between the mosquito vector 
and the human host. The malaria parasite’s life cycle is very complex and involves many distinct 
stages. As the mosquito draws blood meal from human, malarial sporozoites enters into the 
human liver and develops into to a mature schizont. A schizont creates thousands of merozoites, 
which bursts out of the cell into the bloodstream, where it infects red blood cells. A few of the 
merozoites mature into gametocytes that may be ingested by another mosquito during subsequent 
feeding (4). Inside the mosquito’s gut, gametocytes are fertilized and then develop into a zygote 
that further transforms to oocysts, eventually releasing sporozoites. Sporozoites are finally 
transmitted to new human host during an infective bite (2). Nearly half of the world’s population 
is at risk of malaria and although efforts to control this disease are on the rise, the disease has not 





malaria parasite has developed resistance against drugs like chloroquine and sulfadoxin-
pyrimethamine (3). Additionally, research suggests that artemisinin resistance is rapidly 
spreading in southeast Asia. There is no drug available that does not have some level of 
resistance (4). Therefore, more research on identifying effective drugs is warranted to eradicate 
this disease.  
Apicoplast 
Plasmodium is a member of the phylum Apicomplexa that consists of an unusual non-
photosynthetic plastid known as Apicoplast (Figure 1). The apicoplast has a 35 kb circular, 
supercoiled DNA and is the smallest of the plastid genomes. Evidence suggests that the 
apicoplast emerged from the chloroplast from a red-algae (9). The chloroplast is surrounded by 
four membranes, resulting from the secondary endosymbiotic event. It is important to note that 
the secondary endosymbiosis is a symbiotic relationship between two eukaryotic cells in which 
one cell contained a plastid (a modified photosynthetic bacterium residing inside a eukaryotic 
cell) and was engulfed by the other eukaryotic cell. As a consequence, P. falciparum has both 
eukaryotic and prokaryotic genomes. The apicoplast has evolved and lost its photosynthetic 
characteristics over time (6). Nevertheless, heme synthesis, fatty acid biosynthesis, isoprenoid 
precursor synthesis and iron-sulfur complex synthesis are four biosynthetic pathways that have 
been found to be associated with the apicoplast (7). Identification of apicoplast-targeting 
sequence confirmed that the proteins required for these biosynthetic pathways are encoded in the 
nucleus that are targeted to apicoplast (8). This suggests that the apicoplast could a promising 





The apicoplast genome consist only of 68 coding genes that include duplicated t-RNAs, 
large and small subunit rRNAs, RNA polymerase subunits, several protein chaperons and 
ribosomal proteins (6, 9). The apicoplast has also retained the minimal autonomy of gene order 
by undergoing several deletions and rearrangements of the genes which resulted in its reduced 
genome size from 150 kb to 35kb (6).  
Replication of the apicoplast genome 
The apicoplast does not encode for genes responsible for the replication of its own 
genome. The majority of the proteins residing in the apicoplast are nuclear encoded and must be 
imported to function properly (10). In the presence of signal peptide, nuclear encoded apicoplast 
proteins are targeted to the organelle through secretory pathway (11). Signal peptide facilitates 
the entry of nascent polyprotein into the endoplasmic reticulum (ER) and with the help of transit 
peptide, the proteins are targeted to apicoplast (12). 
The replication machinery of the apicoplast consists of a primase, a DNA helicase, DNA 
polymerase, single-stranded binding (SSB) proteins, DNA gyrase (topoisomerase) and ligase 
(11). Because the apicoplast is essential to the parasite and the apicoplast cannot function 
without genomic replication, all of these proteins could be considered targets for anti-malarial 
drugs. DNA gyrase is inhibited by fluoroquinolones and ciproflaxin, both of which show anti-
malarial activity (11).  
Prevention of apicoplast replication does not result in immediate cell death; however, 
blocking the replication process does prevent the parasite from entering other host cells. This 
phenomenon is called delayed cell death, which highlights the importance of apicoplast in 





blocking of replication seems plausible by either targeting DNA polymerase or any of the 
proteins mentioned above.  
The apicoplast DNA polymerase 
On the basis of its amino acid sequence, the P. falciparum apicoplast DNA polymerase is 
classified as an atypical A-family polymerase. It is also one of the most widely studied enzymes 
among Prex domain enzymes. Prex (Plasmodium falciparum Plastidic DNA Replication/repair 
Enzyme Complex) is a poly-protein that encodes DNA primase, helicase, and polymerase (14). 
Prokaryotic A-family polymerases generally contain three functional domains: 1) a 5’ to 3’ 
polymerase domain; 2) a 3’-5’ exonuclease domain for proof reading incorrect nucleotide 
incorporations; and 3) a 5’-3’ exonuclease domain which is responsible for removing RNA 
primers from the lagging strand during replication and nick translation in during DNA repair. 
However, apicoplast DNA polymerases in the phylum Apicocomplexa are lacking the 5’-3’ 
exonuclease domain, instead they have an independent gene coding for an this activity (15).  
The apicoplast DNA polymerase is considered to be a promising drug target because it 
targets to the apicoplast and its inhibition, thereby preventing all DNA replication within the 
organelle (13). A high-throughput inhibition assay would be an appropriate experimental 
methodology in exploring effective inhibitors for DNA polymerase (16). The suggested 
methodology would be helpful in studying the inhibitors through different mechanisms: 1) 
Inhibitor that competes for the active site 2) Inhibitor that binds to the active site and also blocks 
the DNA/substrate from binding to the enzyme/polymerase 3) Inhibitor that binds away from 
DNA/substrate binding site and 4) Inhibitor that binds with the substrate forming an inhibitor-





Prior research has widely used the Malaria Box, a library that contains about 400 
compounds that are active against the red blood cell stages of Plasmodium falciparum. These 
compounds were selected from 2 million compounds that were screened by GlaxoSmithKline 
(GSK), Novartis and St. Jude Children’s Research Hospital using a phenotypic assay for parasite 
killing (18). Out of the 400 compounds, 200 are considered to be “drug-like” compounds (for 
oral drug discovery and development) and 200 were “probe-like” compounds that could be used 
as biological tools for malaria search. It is noted that these 400 compounds are unique, such that 
they are different from currently available anti-malarial compounds in the market. These 
compounds have been screened for cytotoxicity and it was found that they are within the range 
considered acceptable for an initial drug discovery program. The purpose of Malaria box was to 
identify novel drug target and compound optimization (19). We previously screened the Malaria 
Box for apPOL inhibitors and identified a single compound (MMV666123) that had inhibitory 
activity against apPOL. We then kinetically characterized the parent compound along with 36 
structural derivatives to improve inhibitor potency. One of these derivatives was crystallized 
with apPOL and the structure of the complex was determined. The structure revealed a novel 
allosteric site that when liganded may prevent the polymerase from achieving the active, closed 
conformation of the enzyme.  
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CHAPTER 2. STRUCTURE AND KINETIC CHARACTERIZATION OF 
PLASMODIUM FALCIPARUM APICOPLAST DNA POLYMERASE (apPOL) 
 
Supreet Kaur and Scott W. Nelson 
From the Roy J. Carver Department of Biochemistry, Biophysics and Molecular Biology, Iowa 
State University, Ames, Iowa 50011 
Modified from a manuscript in preparation for Journal of biological chemistry 
Abstract 
Malaria is caused by parasitic protozoan Plasmodium falciparum, which contains an 
essential organelle referred to as the apicoplast. The apicoplast is a non-photosynthetic plastid 
harboring its own genetic material. A single DNA polymerase, apPOL, is targeted to the 
apicoplast, where it is responsible for replicating and repairing the genome. apPOL does not 
contain direct orthologs in mammals; therefore, it is considered to be a promising drug target for 
the treatment and/or prevention of malaria. The Malaria Box is a collection of 400 compounds, 
selected from a phenotypic screen of nearly four million compounds for activity against the 
blood stage of Plasmodium falciparum. We previously screened the Malaria Box, finding a 
single compound (MMV666123) as a selective inhibitor of apPOL. Steady-state kinetics indicate 
that the mechanism of inhibition is non-competitive against deoxynucleotides. A structure-
activity relationship analysis of MMV666123 was performed using 36 derivatives. One 
derivative class of MMV666123 facilitated crystal structure determinations of inhibitor-apPOL 
complexes. These derivatives bind to a novel allosteric pocket approximately 20 Å from the 
active site. Derivative binding to the allosteric site could prevent the polymerase from adopting 






Malaria is a deadly disease caused by protozoans Plasmodium falciparum and 
Plasmodium vivax among other species belonging to the genus Plasmodium. According to the 
WHO malaria report, about 435,000 deaths in 2017 were due to malaria (1). Children under 5 
years of age are most affected by this disease in tropical and sub-tropical regions (2). Around 
half the world’s population is under the threat of malaria (1). With the rapid emergence of 
malaria parasites resistant to standard drugs (chloroquine, sulfadoxine–pyrimethamine, 
mefloquine, amodiaquine and artemisinin), there is an urgent need for drugs that target novel 
features of disease progression (3). The identification of potential drug targets and the 
development of potent inhibitors of those targets is one of several approaches, the combination 
of which will eliminate this disease.  
  Plasmodium organisms of the phylum Apicoplexa have an non-photosynthetic plastid 
known as apicoplast that is indispensable for the parasite’s existence (3). Other parasites of the 
phylum Apicoplexa are responsible for diseases of humans such as Toxoplasmosis, 
Cyclosporiasis, and Cystoisosporiasis, and diseases of livestock such as Babesiosis, Theileriosis, 
and Coccidiosis (4). Studies support that apicoplast has evolved from the chloroplast of red algae 
from secondary endoplasmic events (5). With the course of time during its evolution, the 
apicoplast lost its photosynthetic characteristics (13). However, it retained biosynthetic pathways 
for heme, fatty acid, isoprenoid precursor and iron-sulfur complex synthesis (6).  
The apicoplast genome lacks genes for DNA replication. However, the nuclear genome 
has a gene named Plastidic DNA Replication/repair Enzyme Complex (Prex). Prex encodes a 





the endoplasmic reticulum (ER), ultimately reaching the apicoplast with the help of apicoplast 
targeting sequence (3). DNA replication is the process of producing two identical copies of an 
organism’s genetic information. The central enzyme involved in replication is the DNA 
polymerase, which catalyzes the addition of deoxyribose mononucleotides to the 3'-end of the 
primer of a DNA primer/template complex.  
On the basis of sequence, DNA polymerases fall into different families: A, B, C, D, X, Y, 
and reverse transcriptase (RT). The A-family DNA polymerases include some of the best 
structurally and biochemically characterized polymerases (7). All DNA polymerases resemble 
the shape of a human right-hand, with the thumb, a palm and fingers representing separate 
domains, all of which play a role in DNA replication. The palm activates the 3'-hydroxyl of the 
primer, catalyzing the nucleophilic displacement of pyrophosphate from deoxynucleoside 
triphosphates (dNTPs) bound primarily to the fingers domain. The thumb domain positions the 
duple moiety of the DNA primer/template, and plays a role in translocation and processivity (7). 
dNTPs that complement the template by correct Watson-Crick base pairing, drive the fingers 
domain from an open to a closed (catalytically productive) conformational state .“Enforced” 
Watson-Crick interactions at polymerase active site is a major factor in governing the fidelity of 
the polymerase (7). apPOL also undergoes opening and closing conformational changes with 
high rates of fidelity (4,7). X-ray crystal structures have demonstrated that all DNA polymerase 
families share a similar palm domain, but there is a lack of homology in the thumb and finger 
domains.  
DNA replication is indispensable for the proliferation and the survival of all living 
organisms (9). Because of this, DNA replication has been a target of many therapeutic strategies 





polymerase of prokaryotic origin, therefore selective inhibition of its activity should be possible. 
Studies suggest that apPOL is indispensable for the apicoplast genome’s replication (10) (2). 
Known inhibitors of prokaryotic DNA replication, such as ciprofloxacin, inhibit apicoplast DNA 
replication and cause a “delayed death” phenotype in Plasmodium parasites. Delayed death is a 
phenomenon in which the drug does not directly kill the parasite; instead, parasite progenies are 
unable to complete their replicative cycle. Even if the drugs are discontinued before the 
completion of the parent’s life cycle, the progeny still die (10). This suggests that the apicoplast 
could be a promising drug target for malaria treatment and/or prevention and could even be used 
to boost natural immunity to the parasite (11).  
In order to determine compounds that inhibit apPOL, we screened the 400 compound 
Malaria Box using an in vitro DNA synthesis assay and identified one compound (MMV66123) 
that showed selective inhibition of apPOL. Inhibition parameters and the mechanism of 
inhibition of the compound were determined by kinetics and determined that it is non-
competitive against dNTPs with two binding sites. Similarly, the IC50 of 36 derivatives of 
MMV666123 were determined, along with an x-ray crystal structure of one of the derivatives 
bound to apPOL. The structure is consistent with the results of kinetics and suggests 
modification to the inhibitor structure that may lead to tighter binding.  
Materials and Methods 
Materials 
Nickel-agarose was sourced from Sigma-Aldrich Chemical Company and 
deoxyribonucleotides were bought from Thermo Fischer Scientific. Derivatives of the inhibitor 





substrate with Cy3 dye at the 5'-end and Black Hole Quencher-1 at the 3'-end was synthesized by 
Integrated DNA Technologies. pET-SUMO vector and SUMO protease for crystallization were 
prepared by Morgan Milton. PEG 1,000 was bought from Hampton Research. Spin-X centrifuge 
tube filters used for filtration of protein were purchased from Sigma-Aldrich. 
Protein purification 
The purification procedure was identical for the wild type and exonuclease deficient 
polymerases. E. coli BL21 (DE3) cells were transformed with pet28-apPOLexo− C terminal 
polyhistidine tag vector. A single colony was obtained from a LB/kanamycin agar plate and 
transferred to flasks containing 100 ml LB/kanamycin medium. After shaking the flasks for 16h 
at 37°C, 10 ml of the LB starter culture were transferred to two flasks each containing a liter of 
LB.  The flasks were shaken (225 rpm) at 37°C until A600 reached 0.8 and then were cooled to 
18°C by holding them at 4oC for one hour, after which apPOL expression was induced by adding 
200 μM (final) isopropyl β-D-1-thiogalactopyranoside (IPTG). After 16 h with constant shaking 
at 16°C, the cells were collected by centrifugation at 4000 rpm for 10 minutes. After constant 
shaking, the pellet was obtained and was re-suspended in 20 mL nickel binding buffer (20 mM 
Tris, 500 mM NaCl, 5 mM imidazole, pH 8, 4°C) and passed through a homogenizer at 12,000 
psi. After centrifugation for 50 mins at 17000 rpm, the supernatant was loaded on Ni-agarose 
resin. 200 ml of binding buffer and then 100 ml of high salt wash buffer (20 mM Tris, 1 M NaCl, 
25 mM imidazole and 20% glycerol, pH 8.0, 4°C) were passed through the column which was 
then followed by 30 ml (20 mM Tris-HCl, 500 mM NaCl, 20 mM imidazole and 20% glycerol, 
pH 8.0, 4°C). Then the elution buffer (20 mM Tris-HCl, 200 mM NaCl, 150 mM imidazole and 
20% glycerol, pH 8.0, 4°C) was used to obtain the protein. The protein was then concentrated to 





M−1 cm−1. Aliquots of purified apPOLexo−were flash-frozen in liquid nitrogen and stored at 193 
K. The freezing/thawing process does not affect the polymerase activity.  
For crystallization of apPOL with inhibitors, the following steps were performed. First, a 
N-terminal polyhistidyl-SUMO (Small Ubiquitin-like Modifier) tag was inserted before the N-
terminal residue of apPOL protein through molecular cloning. The SUMO tagged apPOL was 
then expressed and purified with nickel-NTA agarose column chromatography. Second, after 
eluting the protein from the nickel-NTA agarose column, it was further purified through 
TOYOPEARL HW-50F (150 mL) gravity column (TOSOH), which was previously equilibrated 
with 20 mM Tris-HCl, 400 mM NaCl, pH 8.0 at 4°C. Fractions were analyzed using Bradford 
assays and SDS-PAGE and those containing apPOL were pooled. The purified protein was 
incubated for 16 hours at 4°C with a 1:50 protein to SUMO protease ratio. SUMO protease 
specifically cuts the amide linkage after the C-terminal residue of the SUMO domain. Thereafter, 
the protein solution was passed through the nickel-NTA-agarose column, retaining the unwanted 
polyhistidyl-SUMO fragment and passing the tag-free apPOL. The tag-less protein was 
confirmed by SDS-PAGE using Coomassie Blue stain, and concentrated to 12 mg/ml. Freshly 
prepared apPOL was passed through a cellulose acetate Spin-X centrifuge tube filter (0.22 μm 
pore size), and then used in crystallization experiments. 
Kinetic experiments 
Assays of apPOLexo− employed a DNA hairpin substrate in 20 mM Tris-HCl, 10 mM 
magnesium acetate, 50 mM potassium acetate, pH 8.0 at 25 °C. Reactions used glass cuvettes 
and a reaction volume of 280 mL. Progress curves of were monitored with a Cary Eclipse 
Fluorescence Spectrophotometer. An excitation and emission wavelength of 545 nm and 570 nm 





software. Inhibition assays used a 96-well plate and plate reader at the same wavelengths. The 
assays were carried out for 20 minutes at an enzyme and dNTP concentration of 20 nM and 16 
mM, respectively. A time course at these concentrations confirmed the linearity of the reaction. 
MMV666123 (referred to here as PC-01-171D) was identified as an inhibitor of 
apPOLexo− through high-throughput screening. The IC50 of PC-01-171D for apPOL was 
determined using 20 nM apPOLexo−, 16 μM dNTPs and 100 nM DNA substrate with varying 
concentration of PC-01-171D from 0-40 μM. PC-01-171D was incubated with apPOLexo− for 10 
minutes in 96 well plate. With the addition of DNA substrate, the reaction was started with the 
help of dNTPs for 20 minutes. Finally, the reaction was quenched using 0.05 M 
ethylenediaminetetraacetic acid (EDTA). IC50 values were determined through Sigma plot 
software. Similarly, IC50 for all the derivatives of PC-01-171D were determined. 
The inhibition mechanism of PC-01-171D versus nucleotides was also performed in 96 
well plates by varying inhibitor concentration from 0 to 6 μM and dNTPs concentrations from 0 
to 128 μM. DNA substrate and apPOLexo− concentrations were kept constant at 100 nM and 20 
nM, respectively. We used Dynafit software to fit the resulting data against inhibition models 
containing competitive, noncompetitive, mixed, and uncompetitive inhibition.  
Crystallization and data collection 
In general, the inhibitors exhibited limited solubility in aqueous buffers (as determined 
visually). As the urea-based derivatives (such as PC-01-194) seemed most soluble in aqueous 
buffers, these were tried first. Solid inhibitor was added incrementally to a concentrated solution 





minutes. Excess (undissolved) inhibitor was removed by centrifugation. Each inhibitor required a 
separate preparation of an inhibitor-saturated apPOL solution. 
Crystallization experiments four commercial screens (PEGRx, SaltRx, Morpheus, and 
Structure) in 96-well sitting-drop plates obtained from Hampton Research. Screening employed a 
Mosquito Crystallization Robot in the X-Ray facility at Iowa State University. Out of 400 
conditions, one condition produced crystals. The results were successfully replicated and then 
optimized manually by the method hanging-drop vapor diffusion. In so doing, the apPOL-
saturated inhibitor solution in 20 mM Tris-HCl, 400 mM NaCl, pH 8.0 was mixed with the well 
solution in equal ratio, producing an initial droplet. Identical crystallization experiments of the 
protein inhibitor complexes were kept at room temperature and at 4°C. A third set of experiments 
had 400 mM NaCl in the well solution before combining 1:1 with the protein solution. The latter 
experiment was pursued to force the migration of water from the droplet to the well. After crystal 
formation, the crystals were looped and immediately plunged into liquid nitrogen for storage and 
subsequent data collection.  
The data of diffraction was collected on Advanced Photon Source beamline 23-ID-D at 
100 K. 600 frames were collected using an oscillation range of 0.2° with a 20 μm beam. HKL-
3000 was used for data processing. Molecular replacement was performed using the PHENIX 
software suite, followed by model building and refinement using Phenix.refine and Coot. 
 
Results and Discussion 
Protein purification 
The yield of apPOLexo− was approximately 25 mg in a liter of Luria broth. The SUMO tag 





A spin concentrator was then used to concentrate the tag-less protein to 12 mg/mL. As with N- 
and C-terminal polyhistidyl constructs of apPOL, the presence of 400 mM NaCl prevents 
precipitation of the protein at concentrations of 12 mg/mL. 
Kinetic experiments 
A stem-loop oligonucleotide with a primer annealed to the loop and a Cy3 fluorophore at 
5’ end and Black Hole Quencher at 3’ end of the stem was used as a DNA substrate for the DNA 
synthesis assays (Figure 2). apPOL extends the primer at the 3'-end and performs strand 
displacement synthesis when it reaches the stem section. This opens the DNA duplex and 
separates the Cy3 fluorophore from the quencher, causing increased fluorescence. We performed 
fluorescence assays varying concentrations of apPOLexo− and found the reaction to be 
approximately linear (Figure 3A). Additionally, we observed that apPOLexo− was stable for 
several hours and multiple preparations of apPOLexo− had similar activity. Continuous and 
stopped-time assays were conducted and we observed linearity for approximately 20 minutes 
(Figure 3B & 3C).  
We used apPOLexo− activity as an output to measure the IC50 of the parent compound, PC-
01-171-D at varying concentrations (Figure 4A & 4B). For this compound, we determined an 
IC50 of 5.0 μM. Using Dynafit software, the concentrations of dNTPs and PC-01-171-D were 
varied on Km and IC50. We noted that the best-fit model was a true noncompetitive with two 
independent binding sites of different affinities (i.e., two molecules of inhibitor can bind per 
enzyme). The Ki of high-affinity binding site was 0.6 μM whereas the Ki of low-affinity binding 
site was 12 μM (Figure 4C). The parent compound has a moderate IC50 and displays 100% 
inhibition activity at 10 μM; however, it does not meet the guidelines suggested by the 





are 1) IC50 is less than 10 nM against target; 2) The compound is soluble; and 3) The compound 
is stable for 24 months. In order to improve the properties of PC-01-171-D, several derivatives 
were synthesized by Pratik Chheda in the Kerns laboratory at the University of Iowa. These 
derivatives included sulfonamide and urea-based analogs (Figure 5). IC50’s were measured for 
the 36 derivatives to define structure-activity relationships and determine whether any derivative 
showed improved inhibitory properties (Figure 6 A and 6B). We noted that the structural 
differences between the derivatives resulted in different values of IC50s. At least three 
derivatives: PC-01-171-C, PC-01-186, and PC-01-194 retained the inhibitory properties of the 
parent compound (100% inhibition activity at 10 μM), but were more soluble based on a visual 
analysis; however, none of the 36 compounds were significantly better inhibitors.  
Crystallization 
Structural work pursued the urea-based derivatives of PC-01-171-D, because of their 
higher solubility and comparable IC50 values. Crystals were obtained by the hanging-drop 
method in droplets containing a 1:1 ratio of inhibitor-saturated protein solution and well solution, 
and grew from 0.1 M sodium citrate tribasic dihydrate pH 5.5, 30% w/v polyethylene glycol 
1000 (PEGRx 1 condition No.17). However, after four days at the room temperature, crystals 
began to dissolve, and disappeared after a week. Crystals were stable (for at least a month) and 
bigger in size if crystal plates were kept at 4 °C and/or if 400 mM NaCl was added to the well 
solution, before combination with the protein solution. This indicates that the optimum 
temperature and condition to obtain stable crystals is 4 °C and excess NaCl. Next, we found that 
the crystals resembled (see Figure 8) the leaf of a flower with an approximate dimension of 200 
× 50 × 50 μm (Figure 7). We note that the crystals obtained were larger in size and much more 






A 20 μm microbeam provided diffraction from crystals of the apPOL-PC-01-194 
complex to a resolution of 2.7 Å with an exposure time of 0.1 seconds per frame. Previous 
crystals formed from protein with the N- or C-terminal hexahistidine tags diffracted to 2.9 Å, 
suggesting that either the presence of the compound or the lack of tags results in a slight 
improvement in overall resolution. Data reduction indicated a space group P65 with unit-cell 
parameters a = b =145.4, c= 164.9 Å, α = β = 90, γ = 120°. The number of observations used in 
refinement were 54,200 with R-work (last shell) = 0.19 (0.29) and R-free (last shell) = 0.24 
(0.33). The position of the inhibitor bound to apPOL is distal to the polymerase active site, which 
is consistent with the non-competitive kinetic mechanism that was determined (Figure 9).  
The asymmetric unit of the crystal contains two polypeptides chains of apPOL (Chain A 
and Chain B). Each chain has at least two bound chloride ions. We have found apPOL to be 
somewhat unstable at NaCl concentrations less than 400 mM, therefore the protein is stored and 
crystallized in the presence of 400 mM NaCl. The observed chloride near the polymerase active 
site (interacting with Lys412, Gln413, Lys417, Glu615) has four hydrogen bonds with proton donors 
(Figure 10). Similarly, there is a second chloride present near the PC-01-194 binding site 
(interacting with Asn234, Asn433, Asn529, Lys531) (Figure 11). Asn433 of the inhibitor binding site 
comes from the other polypeptide chain of asymmetric unit. This chloride ion appears to prevent 
the inhibitor from binding in its “optimal” conformation (the optimal binding mode is in Figure 






Two molecules of PC-01-194 are present among the apPOL chains of the asymmetric 
unit where inhibitor #1binds at Chain A while inhibitor #2 bounds at Chain B. Hydrogen bond is 
present between N11 of inhibitor # 2, Ser 525 (chain B) and Thr 526 (chain B) (Figure13).  
At the tri-methyl end of the PC-01-194 binding pocket lies a highly conserved aromatic 
residue (Trp512 in apPOL). All A-family polymerases undergo repeated cycles of opening and 
closing their finger and thumbs domains when correct incoming nucleotide H-bonds with the 
templating base at the polymerase active site. This closing of the polymerase around the Watson-
Crick base pairs is thought to be the structural basis for polymerase fidelity (8). A comparison of 
the open and closed states of the A-family polymerase from Thermus aquaticus (Klentaq), 
indicates that this conserved aromatic residue (Trp706) moves 4 Å into the compound’s binding 
pocket in the closed state of the enzyme. Assuming apPOL undergoes a similar conformational 
change in the closed conformation, the trimethyl group PC-01-194 would clash with the indol 
nitrogen of Trp512 (Figure 14). This strongly suggests that mechanism of inhibition of PC-01-194 
is to prevent the closed, active conformation of the polymerase by sterically blocking the 
movement of Trp512.    
It is important to note that the binding pocket for PC-01-194 is found in all A-family 
DNA polymerases, although the identities of the residues lining the pocket are only partially 
conserved. The lack of conservation with the three human A-family polymerases (theta, nu, and 
gamma), Figure 15 suggest that PC-01-194 would have low affinity for these enzymes, 
consistent with the observation that the parent compound is non-toxic to a variety of different 
human cells lines (12). The ubiquitous presence of this allosteric pocket in A-family polymerases 
suggests that it could be targeted to control the activity of other medically relevant A-family 
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Figure 2. A schematic of DNA substrate and the steps leading to an increase in fluorescence. 
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Figure 3. Polymerase activity. (A) Optimal concentration of polymerase was identified to be 20 
nM for inhibition assays. (B) Time course showing the polymerase-dependent increase in 
fluorescence using the substrate. (C) Time points to optimize reaction time. The optimum 



























Figure 4. Mechanism of the parent compound of MMV666123 (named as PC-01-171D). (A) 
Structure of PC-01-171D. (B) The IC50 of PC-01-171D was determined by the percentage of 
polymerase activity at variable concentrations of PC-01-171D in μM. Data were fit to the 
standard IC50 equation and an IC50 of 5.0 μM was determined. (C) Plots between initial velocity 
and dNTPs concentration of PC-01-171D (0 μM, 2 μM, 4 μM and 6 μM). The solid lines 
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Figure 9. Crystal structure of apPOL-inhibitor complex. (A). Structure and IC50 of PC-01-194. 









































Figure 13. Hydrogen bond of N11 of inhibitor with Ser525 and Thr526 













Figure 14. Possible mechanism of PC-01-194. Green color shows the open confirmation of 
apPOL and cyan shows the closed confirmation of klentag. Closed confirmation is blocked due 














Figure 15. Residues lining the pocket showing lack of conservation with the three human A-












CHAPTER 3. CONCLUSION 
In this thesis, I determined the IC50 and preliminary kinetic mechanism of the 
MMV666123, an apPOL inhibitor that was selected from the 400 compounds of Malaria Box. It 
was found that the compound did not meet the suggested guidelines presented by Medicine for 
Malaria Venture (MMV). In an attempt to develop a better compound, several derivatives were 
synthesized with a few modifications in the structure by our collaborators. However, the 
unguided modification of the derivatives did not lead us to improved properties. Therefore, it 
was decided that structural characterization of the compounds would be necessary for 
meaningful improvements in inhibitor potency.  
Co-crystallization was performed to explore the apPOL-inhibitor complex. The crystal 
structure of apPOL with the inhibitor PC-01-194 was consistent with the kinetic mechanism 
experiments, which showed two binding sites with different affinities. However, preliminary data 
of another crystal structure of apPOL with the inhibitor PC-01-188 exhibited the same type of 
binding in two sites that had similar affinities. These intriguing results reveal the necessity for 
exploring other derivatives for possible kinetic mechanisms that can explain the polymerase-
inhibitor interaction. 
Future work will include examining the impacts of point mutations. Moreover, the 
substrate can be bound to the crystal structure of apPOL and inhibitor so that we can have a 
better understanding of the inhibition mechanism. In so doing, this would guide our collaborators 
to build more potent and specific variations in the compounds that inhibit apPOL.  
Additionally, future work can address the challenges posed by the presence of chloride 





obtaining its optimal conformation. To overcome this problem, co-crystallization can be 
performed by reducing the amount of NaCl in the well solution. Another way to address this 
problem would be to get rid of the excess of NaCl by letting the crystal grow at 4 °C. 
 
 
 
 
 
 
 
 
 
 
 
 
